Table of Content

1 PD-1/PD-L1 Immunotherapy Market Overview
1.1 Product Overview and Scope of PD-1/PD-L1 Immunotherapy
1.2 PD-1/PD-L1 Immunotherapy Segment by Type
1.2.1 Global PD-1/PD-L1 Immunotherapy Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 PD-1/PD-L1 Immunotherapy Segment by Application
1.3.1 PD-1/PD-L1 Immunotherapy Sales Comparison by Application: (2021-2027)
1.3.2 Non-Small Cell Lung Cancer
1.3.3 Esophageal Cancer
1.3.4 Urothelial Carcinoma
1.3.5 Hepatocellular Carcinoma
1.3.6 Small Cell Lung Cancer
1.3.7 Others
1.4 Global PD-1/PD-L1 Immunotherapy Market Size Estimates and Forecasts
1.4.1 Global PD-1/PD-L1 Immunotherapy Revenue 2016-2027
1.4.2 Global PD-1/PD-L1 Immunotherapy Sales 2016-2027
1.4.3 PD-1/PD-L1 Immunotherapy Market Size by Region: 2016 Versus 2021 Versus 2027

2 PD-1/PD-L1 Immunotherapy Market Competition by Manufacturers
2.1 Global PD-1/PD-L1 Immunotherapy Sales Market Share by Manufacturers (2016-2021)
2.2 Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2016-2021)
2.3 Global PD-1/PD-L1 Immunotherapy Average Price by Manufacturers (2016-2021)
2.4 Manufacturers PD-1/PD-L1 Immunotherapy Manufacturing Sites, Area Served, Product Type
2.5 PD-1/PD-L1 Immunotherapy Market Competitive Situation and Trends
2.5.1 PD-1/PD-L1 Immunotherapy Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest PD-1/PD-L1 Immunotherapy Players Market Share by Revenue
2.5.3 Global PD-1/PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 PD-1/PD-L1 Immunotherapy Retrospective Market Scenario by Region
3.1 Global PD-1/PD-L1 Immunotherapy Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global PD-1/PD-L1 Immunotherapy Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America PD-1/PD-L1 Immunotherapy Market Facts & Figures by Country
3.3.1 North America PD-1/PD-L1 Immunotherapy Sales by Country
3.3.2 North America PD-1/PD-L1 Immunotherapy Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe PD-1/PD-L1 Immunotherapy Market Facts & Figures by Country
3.4.1 Europe PD-1/PD-L1 Immunotherapy Sales by Country
3.4.2 Europe PD-1/PD-L1 Immunotherapy Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific PD-1/PD-L1 Immunotherapy Market Facts & Figures by Region
3.5.1 Asia Pacific PD-1/PD-L1 Immunotherapy Sales by Region
3.5.2 Asia Pacific PD-1/PD-L1 Immunotherapy Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America PD-1/PD-L1 Immunotherapy Market Facts & Figures by Country
3.6.1 Latin America PD-1/PD-L1 Immunotherapy Sales by Country
3.6.2 Latin America PD-1/PD-L1 Immunotherapy Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa PD-1/PD-L1 Immunotherapy Market Facts & Figures by Country
3.7.1 Middle East and Africa PD-1/PD-L1 Immunotherapy Sales by Country
3.7.2 Middle East and Africa PD-1/PD-L1 Immunotherapy Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global PD-1/PD-L1 Immunotherapy Historic Market Analysis by Type
4.1 Global PD-1/PD-L1 Immunotherapy Sales Market Share by Type (2016-2021)
4.2 Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Type (2016-2021)
4.3 Global PD-1/PD-L1 Immunotherapy Price by Type (2016-2021)

5 Global PD-1/PD-L1 Immunotherapy Historic Market Analysis by Application
5.1 Global PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2021)
5.2 Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Application (2016-2021)
5.3 Global PD-1/PD-L1 Immunotherapy Price by Application (2016-2021)

6 Key Companies Profiled
6.1 AstraZeneca Plc
6.1.1 AstraZeneca Plc Corporation Information
6.1.2 AstraZeneca Plc Description and Business Overview
6.1.3 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.1.4 AstraZeneca Plc Product Portfolio
6.1.5 AstraZeneca Plc Recent Developments/Updates
6.2 BeiGene, Ltd.
6.2.1 BeiGene, Ltd. Corporation Information
6.2.2 BeiGene, Ltd. Description and Business Overview
6.2.3 BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.2.4 BeiGene, Ltd. Product Portfolio
6.2.5 BeiGene, Ltd. Recent Developments/Updates
6.3 Bristol-Myers Squibb Company
6.3.1 Bristol-Myers Squibb Company Corporation Information
6.3.2 Bristol-Myers Squibb Company Description and Business Overview
6.3.3 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Bristol-Myers Squibb Company Product Portfolio
6.3.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
6.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Corporation Information
6.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Description and Business Overview
6.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Product Portfolio
6.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments/Updates
6.5 Eli Lilly & Company
6.5.1 Eli Lilly & Company Corporation Information
6.5.2 Eli Lilly & Company Description and Business Overview
6.5.3 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Eli Lilly & Company Product Portfolio
6.5.5 Eli Lilly & Company Recent Developments/Updates
6.6 F. Hoffmann-La Roche Ltd
6.6.1 F. Hoffmann-La Roche Ltd Corporation Information
6.6.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.6.3 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.6.4 F. Hoffmann-La Roche Ltd Product Portfolio
6.6.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.7 GlaxoSmithKline plc
6.6.1 GlaxoSmithKline plc Corporation Information
6.6.2 GlaxoSmithKline plc Description and Business Overview
6.6.3 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GlaxoSmithKline plc Product Portfolio
6.7.5 GlaxoSmithKline plc Recent Developments/Updates
6.8 Innovent Biologics, Inc.
6.8.1 Innovent Biologics, Inc. Corporation Information
6.8.2 Innovent Biologics, Inc. Description and Business Overview
6.8.3 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Innovent Biologics, Inc. Product Portfolio
6.8.5 Innovent Biologics, Inc. Recent Developments/Updates
6.9 Jiangsu HengRui Medicine Co., Ltd.
6.9.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.9.2 Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
6.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Jiangsu HengRui Medicine Co., Ltd. Product Portfolio
6.9.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
6.10 Merck & Co., Inc.
6.10.1 Merck & Co., Inc. Corporation Information
6.10.2 Merck & Co., Inc. Description and Business Overview
6.10.3 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck & Co., Inc. Product Portfolio
6.10.5 Merck & Co., Inc. Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Corporation Information
6.11.2 Novartis AG PD-1/PD-L1 Immunotherapy Description and Business Overview
6.11.3 Novartis AG PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Novartis AG Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 Pfizer Inc.
6.12.1 Pfizer Inc. Corporation Information
6.12.2 Pfizer Inc. PD-1/PD-L1 Immunotherapy Description and Business Overview
6.12.3 Pfizer Inc. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Pfizer Inc. Product Portfolio
6.12.5 Pfizer Inc. Recent Developments/Updates
6.13 Regeneron Pharmaceuticals Inc.
6.13.1 Regeneron Pharmaceuticals Inc. Corporation Information
6.13.2 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Description and Business Overview
6.13.3 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Regeneron Pharmaceuticals Inc. Product Portfolio
6.13.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
6.14 Sanofi S.A.
6.14.1 Sanofi S.A. Corporation Information
6.14.2 Sanofi S.A. PD-1/PD-L1 Immunotherapy Description and Business Overview
6.14.3 Sanofi S.A. PD-1/PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Sanofi S.A. Product Portfolio
6.14.5 Sanofi S.A. Recent Developments/Updates

7 PD-1/PD-L1 Immunotherapy Manufacturing Cost Analysis
7.1 PD-1/PD-L1 Immunotherapy Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of PD-1/PD-L1 Immunotherapy
7.4 PD-1/PD-L1 Immunotherapy Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 PD-1/PD-L1 Immunotherapy Distributors List
8.3 PD-1/PD-L1 Immunotherapy Customers

9 PD-1/PD-L1 Immunotherapy Market Dynamics
9.1 PD-1/PD-L1 Immunotherapy Industry Trends
9.2 PD-1/PD-L1 Immunotherapy Growth Drivers
9.3 PD-1/PD-L1 Immunotherapy Market Challenges
9.4 PD-1/PD-L1 Immunotherapy Market Restraints

10 Global Market Forecast
10.1 PD-1/PD-L1 Immunotherapy Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of PD-1/PD-L1 Immunotherapy by Type (2022-2027)
10.1.2 Global Forecasted Revenue of PD-1/PD-L1 Immunotherapy by Type (2022-2027)
10.2 PD-1/PD-L1 Immunotherapy Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of PD-1/PD-L1 Immunotherapy by Application (2022-2027)
10.2.2 Global Forecasted Revenue of PD-1/PD-L1 Immunotherapy by Application (2022-2027)
10.3 PD-1/PD-L1 Immunotherapy Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of PD-1/PD-L1 Immunotherapy by Region (2022-2027)
10.3.2 Global Forecasted Revenue of PD-1/PD-L1 Immunotherapy by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global PD-1/PD-L1 Immunotherapy Sales (Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global PD-1/PD-L1 Immunotherapy Sales (Units) Comparison by Application (2021-2027)
Table 3. Global PD-1/PD-L1 Immunotherapy Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers PD-1/PD-L1 Immunotherapy Covered in This Study
Table 5. Global PD-1/PD-L1 Immunotherapy Sales (Units) of Key Manufacturers (2016-2021)
Table 6. Global PD-1/PD-L1 Immunotherapy Sales Share by Manufacturers (2016-2021)
Table 7. Global PD-1/PD-L1 Immunotherapy Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global PD-1/PD-L1 Immunotherapy Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market PD-1/PD-L1 Immunotherapy Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers PD-1/PD-L1 Immunotherapy Manufacturing Sites and Area Served
Table 11. Manufacturers PD-1/PD-L1 Immunotherapy Product Type
Table 12. Global PD-1/PD-L1 Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global PD-1/PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1/PD-L1 Immunotherapy as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global PD-1/PD-L1 Immunotherapy Sales by Region (2016-2021) & (Units)
Table 16. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Region (2016-2021)
Table 17. Global PD-1/PD-L1 Immunotherapy Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021) & (Units)
Table 19. North America PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2021)
Table 20. North America PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2021)
Table 22. Europe PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021) & (Units)
Table 23. Europe PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2021)
Table 24. Europe PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific PD-1/PD-L1 Immunotherapy Sales by Region (2016-2021) & (Units)
Table 27. Asia Pacific PD-1/PD-L1 Immunotherapy Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific PD-1/PD-L1 Immunotherapy Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific PD-1/PD-L1 Immunotherapy Revenue Market Share by Region (2016-2021)
Table 30. Latin America PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021) & (Units)
Table 31. Latin America PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2021)
Table 32. Latin America PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021) & (Units)
Table 35. Middle East and Africa PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2021)
Table 38. Global PD-1/PD-L1 Immunotherapy Sales (Units) by Type (2016-2021)
Table 39. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Type (2016-2021)
Table 40. Global PD-1/PD-L1 Immunotherapy Revenue (Million US$) by Type (2016-2021)
Table 41. Global PD-1/PD-L1 Immunotherapy Revenue Share by Type (2016-2021)
Table 42. Global PD-1/PD-L1 Immunotherapy Price (US$/Unit) by Type (2016-2021)
Table 43. Global PD-1/PD-L1 Immunotherapy Sales (Units) by Application (2016-2021)
Table 44. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2021)
Table 45. Global PD-1/PD-L1 Immunotherapy Revenue (Million US$) by Application (2016-2021)
Table 46. Global PD-1/PD-L1 Immunotherapy Revenue Share by Application (2016-2021)
Table 47. Global PD-1/PD-L1 Immunotherapy Price (US$/Unit) by Application (2016-2021)
Table 48. AstraZeneca Plc Corporation Information
Table 49. AstraZeneca Plc Description and Business Overview
Table 50. AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product
Table 52. AstraZeneca Plc Recent Developments/Updates
Table 53. BeiGene, Ltd. Corporation Information
Table 54. BeiGene, Ltd. Description and Business Overview
Table 55. BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Product
Table 57. BeiGene, Ltd. Recent Developments/Updates
Table 58. Bristol-Myers Squibb Company Corporation Information
Table 59. Bristol-Myers Squibb Company Description and Business Overview
Table 60. Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product
Table 62. Bristol-Myers Squibb Company Recent Developments/Updates
Table 63. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Corporation Information
Table 64. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Description and Business Overview
Table 65. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Product
Table 67. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments/Updates
Table 68. Eli Lilly & Company Corporation Information
Table 69. Eli Lilly & Company Description and Business Overview
Table 70. Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product
Table 72. Eli Lilly & Company Recent Developments/Updates
Table 73. F. Hoffmann-La Roche Ltd Corporation Information
Table 74. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 75. F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product
Table 77. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 78. GlaxoSmithKline plc Corporation Information
Table 79. GlaxoSmithKline plc Description and Business Overview
Table 80. GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product
Table 82. GlaxoSmithKline plc Recent Developments/Updates
Table 83. Innovent Biologics, Inc. Corporation Information
Table 84. Innovent Biologics, Inc. Description and Business Overview
Table 85. Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Product
Table 87. Innovent Biologics, Inc. Recent Developments/Updates
Table 88. Jiangsu HengRui Medicine Co., Ltd. Corporation Information
Table 89. Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
Table 90. Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Product
Table 92. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 93. Merck & Co., Inc. Corporation Information
Table 94. Merck & Co., Inc. Description and Business Overview
Table 95. Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Product
Table 97. Merck & Co., Inc. Recent Developments/Updates
Table 98. Novartis AG Corporation Information
Table 99. Novartis AG Description and Business Overview
Table 100. Novartis AG PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Novartis AG PD-1/PD-L1 Immunotherapy Product
Table 102. Novartis AG Recent Developments/Updates
Table 103. Pfizer Inc. Corporation Information
Table 104. Pfizer Inc. Description and Business Overview
Table 105. Pfizer Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. Pfizer Inc. PD-1/PD-L1 Immunotherapy Product
Table 107. Pfizer Inc. Recent Developments/Updates
Table 108. Regeneron Pharmaceuticals Inc. Corporation Information
Table 109. Regeneron Pharmaceuticals Inc. Description and Business Overview
Table 110. Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 111. Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Product
Table 112. Regeneron Pharmaceuticals Inc. Recent Developments/Updates
Table 113. Sanofi S.A. Corporation Information
Table 114. Sanofi S.A. Description and Business Overview
Table 115. Sanofi S.A. PD-1/PD-L1 Immunotherapy Sales (Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 116. Sanofi S.A. PD-1/PD-L1 Immunotherapy Product
Table 117. Sanofi S.A. Recent Developments/Updates
Table 118. Production Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. PD-1/PD-L1 Immunotherapy Distributors List
Table 121. PD-1/PD-L1 Immunotherapy Customers List
Table 122. PD-1/PD-L1 Immunotherapy Market Trends
Table 123. PD-1/PD-L1 Immunotherapy Growth Drivers
Table 124. PD-1/PD-L1 Immunotherapy Market Restraints
Table 125. Global PD-1/PD-L1 Immunotherapy Sales Forecast by Type (2022-2027) & (Units)
Table 126. Global PD-1/PD-L1 Immunotherapy Sales Market Share Forecast by Type (2022-2027)
Table 127. Global PD-1/PD-L1 Immunotherapy Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 128. Global PD-1/PD-L1 Immunotherapy Revenue Market Share Forecast by Type (2022-2027)
Table 129. Global PD-1/PD-L1 Immunotherapy Sales Forecast by Application (2022-2027) & (Units)
Table 130. Global PD-1/PD-L1 Immunotherapy Sales Market Share Forecast by Application (2022-2027)
Table 131. Global PD-1/PD-L1 Immunotherapy Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 132. Global PD-1/PD-L1 Immunotherapy Revenue Market Share Forecast by Application (2022-2027)
Table 133. Global PD-1/PD-L1 Immunotherapy Sales Forecast by Region (2022-2027) & (Units)
Table 134. Global PD-1/PD-L1 Immunotherapy Sales Market Share Forecast by Region (2022-2027)
Table 135. Global PD-1/PD-L1 Immunotherapy Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 136. Global PD-1/PD-L1 Immunotherapy Revenue Market Share Forecast by Region (2022-2027)
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of PD-1/PD-L1 Immunotherapy
Figure 2. Global PD-1/PD-L1 Immunotherapy Market Share by Type in 2020 & 2027
Figure 3. PD-1 Inhibitors Product Picture
Figure 4. PD-L1 Inhibitors Product Picture
Figure 5. Global PD-1/PD-L1 Immunotherapy Market Share by Application in 2020 & 2027
Figure 6. Non-Small Cell Lung Cancer
Figure 7. Esophageal Cancer
Figure 8. Urothelial Carcinoma
Figure 9. Hepatocellular Carcinoma
Figure 10. Small Cell Lung Cancer
Figure 11. Others
Figure 12. Global PD-1/PD-L1 Immunotherapy Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global PD-1/PD-L1 Immunotherapy Market Size 2016-2027 (US$ Million)
Figure 14. Global PD-1/PD-L1 Immunotherapy Sales 2016-2027 (Units)
Figure 15. Global PD-1/PD-L1 Immunotherapy Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 16. PD-1/PD-L1 Immunotherapy Sales Share by Manufacturers in 2020
Figure 17. Global PD-1/PD-L1 Immunotherapy Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest PD-1/PD-L1 Immunotherapy Players: Market Share by Revenue in 2020
Figure 19. PD-1/PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Region (2016-2021)
Figure 21. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Region in 2020
Figure 22. Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Region (2016-2021)
Figure 23. Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Region in 2020
Figure 24. U.S. PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. UAE PD-1/PD-L1 Immunotherapy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of PD-1/PD-L1 Immunotherapy by Type (2016-2021)
Figure 49. Sales Market Share of PD-1/PD-L1 Immunotherapy by Application (2016-2021)
Figure 50. Sales Market Share of PD-1/PD-L1 Immunotherapy by Application in 2020
Figure 51. Revenue Share of PD-1/PD-L1 Immunotherapy by Application (2016-2021)
Figure 52. Revenue Share of PD-1/PD-L1 Immunotherapy by Application in 2020
Figure 53. Manufacturing Cost Structure of PD-1/PD-L1 Immunotherapy
Figure 54. Manufacturing Process Analysis of PD-1/PD-L1 Immunotherapy
Figure 55. PD-1/PD-L1 Immunotherapy Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed